Please login to the form below

Not currently logged in


This page shows the latest Aimmune news and features for those working in and with pharma, biotech and healthcare.

DBV refiles peanut allergy immunotherapy in the US

DBV refiles peanut allergy immunotherapy in the US

four to 11 years, as it tries to catch up with a rival programme from US company Aimmune Therapeutics that is already under FDA review. ... Aimmune is expecting an approval decision on AR101 by January 2020, and the FDA has planned an advisory committee

Latest news

More from news
Approximately 4 fully matching, plus 2 partially matching documents found.

Latest Intelligence

  • Orphan drugs and breakthrough therapies drive Cortellis Drugs to Watch 2019 Orphan drugs and breakthrough therapies drive Cortellis Drugs to Watch 2019

    Forecast sales for Skyrizi in 2023 are $1.74bn. AR-101 from Aimmune Therapeutics addresses peanut allergy. ... However, Aimmune reported in February 2019 that the FDA had initially determined that the drug, as an allergenic extract, was exempt from the

  • Drug launches to watch in 2019 Drug launches to watch in 2019

    Now a US biotech company, Aimmune, looks set to bring the first treatment to market by the end of this year. ... Aimmune Therapeutics submitted the drug to the FDA on 21 December.

  • Deal Watch November 2016 Deal Watch November 2016

    licence, collaboration. 167. Aimmune Therapeutics/ Nestlé Health Science. CODIT (Characterised Oral Desensitisation ImmunoTherapy), for treating life-threatening food.

More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.

Featured jobs

Subscribe to our email news alerts


Add my company
Research Partnership

We are the largest independent healthcare market research and consulting agencies in the world. Trusted partner to the global pharmaceutical...

Latest intelligence

Empowered patients: shaking the foundations of healthcare
Precision medicine represents a new paradigm in healthcare.This new approach to treating and preventing disease views the patient holistically, analysing their genes, environment and lifestyle, and using this information to...
A uniquely English genomic medicine service
The UK National Health Service is developing one standardised approach to embedding precision medicine across the whole of England. Blue Latitude Health speaks to Dr Tom Fowler, Deputy Chief Scientist...
Blended Intelligence
Data is the most valued commodity of the modern world. For P&P it's all about the application....